Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 8.01 (Other Events). Phase 2 TOIVA trial data for QTORIN™ rapamycin presented at Society for Investigative Dermatology annual meeting.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 2 TOIVA trial data for QTORIN™ rapamycin presented at Society for Investigative Dermatology annual meeting
- Data concern patients with cutaneous venous malformations, supporting clinical development visibility
- Press release filed as Exhibit 99.1 for detailed efficacy and safety findings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.